var data={"title":"Injectable soft tissue fillers: Permanent agents","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Injectable soft tissue fillers: Permanent agents</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/contributors\" class=\"contributor contributor_credentials\">Alastair Carruthers, FRCPC</a></dd><dd><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/contributors\" class=\"contributor contributor_credentials\">Jean Carruthers, MD, FRCSC</a></dd><dd><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/contributors\" class=\"contributor contributor_credentials\">Shannon Humphrey, MD, FRCPC, FAAD</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/contributors\" class=\"contributor contributor_credentials\">Jeffrey S Dover, MD, FRCPC</a></dd><dd><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/contributors\" class=\"contributor contributor_credentials\">Charles E Butler, MD, FACS</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/contributors\" class=\"contributor contributor_credentials\">Abena O Ofori, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jul 07, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H879724\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Soft tissue fillers are used alone or in combination with other aesthetic procedures to correct wrinkles and to restore tissue volume lost due to aging, lipoatrophy, or other causes. In contrast to resorbable fillers such as <a href=\"topic.htm?path=hyaluronate-derivatives-drug-information\" class=\"drug drug_general\">hyaluronic acid</a>, fillers that contain polymethylmethacrylate microspheres, silicone, or hydrogel polymers persist indefinitely in tissue. Cautious and conservative use of permanent fillers is essential, as improper injection techniques can lead to long-lasting adverse effects.</p><p>The efficacy, use, and adverse effects of permanent soft tissue filling agents will be reviewed here. Information on resorbable soft tissue fillers and an overview of the clinical use and complications of soft tissue fillers are available elsewhere. (See <a href=\"topic.htm?path=injectable-soft-tissue-fillers-temporary-agents\" class=\"medical medical_review\">&quot;Injectable soft tissue fillers: Temporary agents&quot;</a> and <a href=\"topic.htm?path=injectable-soft-tissue-fillers-overview-of-clinical-use\" class=\"medical medical_review\">&quot;Injectable soft tissue fillers: Overview of clinical use&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H3502728\"><span class=\"h1\">PRECAUTIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Many patients can achieve cosmetically pleasing results with temporary fillers, and the decision to utilize a permanent filling agent should be considered carefully. In the event that a <a href=\"topic.htm?path=hyaluronate-derivatives-drug-information\" class=\"drug drug_general\">hyaluronic acid</a> gel (a commonly used temporary filling agent) is placed incorrectly in tissue, the adverse cosmetic result can be rapidly corrected through the administration of <a href=\"topic.htm?path=hyaluronidase-drug-information\" class=\"drug drug_general\">hyaluronidase</a> or can be left to spontaneously resolve over the course of several months as the filler is degraded. In contrast, unfavorable cosmetic results following misplacement of permanent fillers may require surgical intervention and may be difficult or impossible reverse. (See <a href=\"topic.htm?path=injectable-soft-tissue-fillers-temporary-agents#H1117242\" class=\"medical medical_review\">&quot;Injectable soft tissue fillers: Temporary agents&quot;, section on 'Reversal'</a>.)</p><p>Additionally, use of a filling agent with a limited duration of effect provides the clinician with the flexibility to respond to changes in patient preferences and allows the clinician to adjust the placement of fillers in concordance with the cutaneous and structural changes that occur with age over time. Thus, patients who desire treatment with permanent filling agents must be screened carefully. Patients who are unsure of their desired outcomes, who have a history of unsubstantiated poor satisfaction with cosmetic treatments, or who are new to the use of soft tissue fillers are poor candidates for treatment with permanent agents.</p><p>As with semipermanent filling agents, blindness can occur if embolization of a permanent filler substance inhibits perfusion of the central retinal branch of the ophthalmic artery. Most reported cases of blindness following use of a permanent filler have involved autologous fat injections; however, cases of blindness following injection of polymethylmethacrylate microspheres and liquid silicone also have been reported [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/1,2\" class=\"abstract_t\">1,2</a>]. (See <a href=\"topic.htm?path=injectable-soft-tissue-fillers-overview-of-clinical-use#H1196285\" class=\"medical medical_review\">&quot;Injectable soft tissue fillers: Overview of clinical use&quot;, section on 'Early adverse effects'</a> and <a href=\"topic.htm?path=central-and-branch-retinal-artery-occlusion\" class=\"medical medical_review\">&quot;Central and branch retinal artery occlusion&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H15763905\"><span class=\"h1\">POLYMETHYLMETHACRYLATE MICROSPHERES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>ArteFill, which is now known as Bellafill in North America, is a nonbiodegradable injectable filling agent composed of 30 to 50 micrometer polymethylmethacrylate (PMMA) microspheres suspended in a water-based gel containing 3.5% bovine collagen and 0.3% <a href=\"topic.htm?path=lidocaine-drug-information\" class=\"drug drug_general\">lidocaine</a>. Previous formulations of PMMA microspheres were marketed under the names Arteplast and Artecoll. Modifications in microsphere size and product purification methods have improved the biocompatibility of Bellafill compared with its precursors [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/3\" class=\"abstract_t\">3</a>]. </p><p>Bellafill is the only injectable permanent filling agent approved by the US Food and Drug Administration (FDA), and this approval is limited to its use for nasolabial folds. However, the PMMA filler has been used for a variety of other indications, including additional facial wrinkles, contour defects on the face and neck, and acne scars [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/4,5\" class=\"abstract_t\">4,5</a>].</p><p class=\"headingAnchor\" id=\"H873135\"><span class=\"h2\">Mechanism of action</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>After implantation, the bovine collagen component of Bellafill dissipates over the course of one to three months, leaving behind the nonbiodegradable PMMA microspheres [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/6\" class=\"abstract_t\">6</a>]. The microspheres stimulate a local inflammatory reaction that is followed by the deposition of granulation tissue during the first few weeks after implantation [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/3\" class=\"abstract_t\">3</a>]. The connective tissue subsequently matures, and by three months after injection, PMMA microspheres are surrounded by newly formed collagen. The presence of new collagen accounts for the observed volume-filling effect. </p><p class=\"headingAnchor\" id=\"H873242\"><span class=\"h2\">Efficacy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The efficacy of PMMA microspheres for facial wrinkles was evaluated in a randomized trial of 251 patients treated with either a PMMA filler (Artecoll) or a collagen filler (Zyderm II or Zyplast) [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/6\" class=\"abstract_t\">6</a>]. A total of 1334 glabellar frown lines, nasolabial folds, radial upper lip lines, and marionette lines were treated in up to two treatment sessions over the course of one month. Six months after treatment, photographic assessment by masked observers revealed that PMMA was superior to collagen fillers for the treatment of nasolabial folds. Although the masked observers did not detect a statistically significant difference in improvement for the other treated sites at this time point, an extended phase of the study for patients treated with PMMA found statistically significant improvement in wrinkle severity scores compared with baseline values for all four sites at 12 months. In addition, long-term follow-up studies of recipients of PMMA fillers indicate that beneficial effects can persist for at least four to five years [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/7,8\" class=\"abstract_t\">7,8</a>].</p><p class=\"headingAnchor\" id=\"H873142\"><span class=\"h2\">Use</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Similar to other soft tissue fillers that contain bovine collagen, patients must be skin-tested for hypersensitivity reactions to bovine collagen prior to injection. Skin tests are performed with intradermal injection of 0.1 mL of collagen on the ventral forearm four weeks prior to treatment. Patients with positive skin tests should not be treated. PMMA injections are also contraindicated for patients with known allergies to any of the product ingredients or a history of keloid or hypertrophic scar formation. </p><p>Individuals with well-defined lines and furrows and minimal excess skin are good candidates for treatment with PMMA [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/5\" class=\"abstract_t\">5</a>]. Injections are <strong>not</strong> recommended for areas of thin skin, such as the lower eyelid and neck, or for patients with generally thin, loose skin, as the implant may remain palpable or visible [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/9\" class=\"abstract_t\">9</a>]. In addition, PMMA should <strong>not</strong> be used in the lips due to an increased risk for lumpiness or beading after injection.</p><p>Bellafill is supplied in prefilled syringes, and a 26-gauge needle is typically used for injection. The product should be implanted in the deep reticular dermis and overcorrection of defects should be avoided. A series of conservative injections is often required to achieve optimal results. </p><p>Touch-up injections can be performed one to three months after the initial treatment. Because new collagen synthesis contributes to the effect, optimal results occur after approximately 3 to 12 months. Additional improvement more than one year after treatment may also occur [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/7\" class=\"abstract_t\">7</a>]. </p><p class=\"headingAnchor\" id=\"H873149\"><span class=\"h2\">Adverse effects</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Potential complications of PMMA include nodules due to superficial placement, persistent redness or telangiectasias, hypertrophic scarring, or the delayed appearance of granulomas. Granulomas occurred in approximately 2.5 percent of patients treated with Arteplast and 0.02 percent of patients treated with Artecoll [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/4,7,10\" class=\"abstract_t\">4,7,10</a>]. The risk for granuloma formation after treatment with Bellafill appears to be lower than for Artecoll [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/5\" class=\"abstract_t\">5</a>]. </p><p>The utilization of proper injection technique may reduce the risk for adverse effects [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/5\" class=\"abstract_t\">5</a>]. When they occur, granulomas can be treated with intralesional corticosteroid injection. Nodules and hypertrophic scarring also can respond to intralesional corticosteroids [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/5,11\" class=\"abstract_t\">5,11</a>]. </p><p class=\"headingAnchor\" id=\"H15763919\"><span class=\"h1\">HYDROGEL POLYMERS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Hydrogel polymer fillers are synthetic, nonbiodegradable, hydrophilic gels with a high degree of elasticity. </p><p class=\"headingAnchor\" id=\"H873899\"><span class=\"h2\">Polyacrylamide hydrogel</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Available throughout Europe, Australia, Asia, and Mexico, Aquamid and Aquamid Reconstruction are nonbiodegradable filling agents composed of 2.5 percent cross-linked polyacrylamide and 97.5 percent water [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/12\" class=\"abstract_t\">12</a>]. Aquamid Reconstruction is slightly more viscous than Aquamid.</p><p class=\"headingAnchor\" id=\"H874204\"><span class=\"h3\">Mechanism of action</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Polyacrylamide hydrogel augments soft tissue exclusively through a direct, volume-filling effect. The hydrogel becomes an integrated part of the patient's soft tissue.</p><p class=\"headingAnchor\" id=\"H874220\"><span class=\"h3\">Efficacy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Polyacrylamide hydrogel is effective for soft tissue filling [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/13-17\" class=\"abstract_t\">13-17</a>]. In a 12-month randomized trial of 315 patients treated for nasolabial folds, the efficacy of Aquamid was similar to a <a href=\"topic.htm?path=hyaluronate-derivatives-drug-information\" class=\"drug drug_general\">hyaluronic acid</a> filler (Restylane) [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/18\" class=\"abstract_t\">18</a>]. Side effects were mostly mild and transient and similar for both treatment groups. Of note, one serious treatment-related infection occurred among the patients treated with Aquamid. The infection resolved after antibiotic therapy and surgical removal of the product.</p><p>Polyacrylamide hydrogel was also effective for facial soft tissue augmentation in an uncontrolled study of 251 patients with various facial contour or soft tissue defects. After 12 months, 93 percent of the 228 patients who were available for follow-up exhibited good or very good responses to treatment [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/14\" class=\"abstract_t\">14</a>]. The benefits of treatment were long-lasting; similar rates of response were observed in a subset of patients five years after their last treatment [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/19\" class=\"abstract_t\">19</a>].</p><p class=\"headingAnchor\" id=\"H874440\"><span class=\"h3\">Use</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Aquamid and Aquamid Reconstruction are used for the treatment of deep wrinkles and folds and for the correction of facial contours. The products are supplied in prefilled syringes as Aquamid and Aquamid Reconstruction. The more viscous Aquamid Reconstruction is best suited for injections where a large volume of product is required, such as in the treatment of lipoatrophy. Aquamid is injected with a 27-gauge needle, and a 25- or 27-gauge needle is typically utilized for injection of Aquamid Reconstruction. </p><p>Both products should be placed into the subcutaneous fat and overcorrection should be avoided (<a href=\"image.htm?imageKey=DERM%2F54021\" class=\"graphic graphic_figure graphicRef54021 \">figure 1</a>). Polyacrylamide hydrogels should not be used intradermally, and, therefore, are not appropriate for the correction of fine wrinkles.</p><p class=\"headingAnchor\" id=\"H874302\"><span class=\"h3\">Adverse effects</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Polyacrylamide hydrogel appears to be well tolerated; side effects are generally temporary and transient, including swelling, pain, redness, hematoma, or pruritus [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/14,15\" class=\"abstract_t\">14,15</a>]. Other potential side effects include nodule formation, local induration, skin discoloration, and infections [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/19,20\" class=\"abstract_t\">19,20</a>]. Delayed granulomatous reactions, ulceration, bone erosion, and migration of polyacrylamide hydrogel in tissue have been reported in a few patients [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/21-25\" class=\"abstract_t\">21-25</a>].</p><p class=\"headingAnchor\" id=\"H8872500\"><span class=\"h2\">Polyalkylimide hydrogel</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Bio-Alcamid is another nonbiodegradable hydrogel. It consists of 96 percent water and 4 percent synthetic reticulate polymer (polyalkylimide). Bio-Alcamid is not available for use in the United States.</p><p class=\"headingAnchor\" id=\"H882078\"><span class=\"h3\">Mechanism of action</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Once implanted, polyalkylimide hydrogel becomes encapsulated by a very thin rim of collagen, isolating it from the host tissues. Similar to polyacrylamide hydrogel, the product's efficacy results from a direct volume-filling effect.</p><p class=\"headingAnchor\" id=\"H882085\"><span class=\"h3\">Efficacy and use</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Polyalkylimide hydrogel has been studied most extensively for HIV-associated lipoatrophy and has been effective for this indication in a small randomized trial and case series [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/26-32\" class=\"abstract_t\">26-32</a>]. The product has also been used for other indications, including lip augmentation and the cosmetic improvement soft-tissue and bony contour defects [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/28,33,34\" class=\"abstract_t\">28,33,34</a>]. Like polyacrylamide, injections should be placed into the subcutaneous fat (<a href=\"image.htm?imageKey=DERM%2F54021\" class=\"graphic graphic_figure graphicRef54021 \">figure 1</a>).</p><p class=\"headingAnchor\" id=\"H882092\"><span class=\"h3\">Adverse effects</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Common adverse effects of injection include mild and transient swelling, pain, bruising, and erythema [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/32\" class=\"abstract_t\">32</a>]. There have also been reports of infections developing months to years after implantation, delayed inflammatory reactions, and migration of the product in tissue [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/12,35-42\" class=\"abstract_t\">12,35-42</a>]. Granulomas have occurred in at least two patients treated with this agent for lip augmentation [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/41\" class=\"abstract_t\">41</a>].</p><p class=\"headingAnchor\" id=\"H6313044\"><span class=\"h1\">LIQUID INJECTABLE SILICONE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The use of liquid injectable silicone (purified polydimethylsiloxane) for soft-tissue augmentation is controversial due to concern over the potential for long-term complications. Liquid injectable silicone should be utilized only by experienced and expert injectors in carefully selected patients. In the United States, liquid silicone is FDA approved only for intraocular use.</p><p class=\"headingAnchor\" id=\"H6313086\"><span class=\"h2\">Mechanism of action</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The efficacy of liquid injectable silicone as a soft tissue filler results from a combination of a direct volume-filling effect of the injected material and the formation of new collagen around individual silicone microdroplets in tissue [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/43,44\" class=\"abstract_t\">43,44</a>].</p><p class=\"headingAnchor\" id=\"H6313093\"><span class=\"h2\">Efficacy and safety</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>No randomized trials have evaluated the use of liquid injectable silicone for cosmetic soft tissue augmentation. In a retrospective study of 916 patients treated by a single practitioner with liquid injectable silicone (1000-centistoke purified polydimethylsiloxane) for rhytides, acne scars, lip augmentation, or facial contour defects, treatment appeared to be effective and safe [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/45\" class=\"abstract_t\">45</a>]. Adverse effects included signs of overcorrection in 11 patients (1 percent) and hyperpigmentation in one patient. No granulomatous or other persistent inflammatory reactions were noted. A pilot study in which 77 patients were injected with silicone to correct HIV-associated lipoatrophy also found that treatment was well tolerated [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/46\" class=\"abstract_t\">46</a>]. Adverse events were limited to mild and transient pain, edema, erythema, and ecchymoses. </p><p>The possibility of long-term benefit from silicone when used as a facial soft tissue filler was evident in a study in which little or no time-related change in the response of facial HIV-associated lipoatrophy to liquid injectable silicone was observed in all of three patients clinically assessed at both 18 months and 9 years after treatment [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/47\" class=\"abstract_t\">47</a>]. In addition, a questionnaire-based study in which 179 patients treated with liquid injectable silicone for lip augmentation were successfully contacted after three to seven years found that 85 percent of patients rated their results as good or excellent [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/48\" class=\"abstract_t\">48</a>]. Complications were limited to burning or local hematoma immediately after injection (6 percent) and small nodules attributed to improper placement of silicone (2 percent). </p><p>Although the risk for serious adverse effects appears to be less than 1 percent when purified, medical grade silicone is used with proper injection techniques [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/44-46,48-54\" class=\"abstract_t\">44-46,48-54</a>], reports of granulomas, disfiguring nodules, lymphedema, and migration of liquid silicone after injection have led to lasting concern over the use of this agent [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/51,55-64\" class=\"abstract_t\">51,55-64</a>]. Many complications associated with silicone injection have been the result of improper use, large volume injections, or injection of industrial-grade or adulterated products [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/44,65,66\" class=\"abstract_t\">44,65,66</a>]. </p><p>Granulomas may occur weeks to decades after injection and can be severely disfiguring and debilitating [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/51\" class=\"abstract_t\">51</a>]. Treatments have included intralesional corticosteroids, oral <a href=\"topic.htm?path=minocycline-drug-information\" class=\"drug drug_general\">minocycline</a> or <a href=\"topic.htm?path=doxycycline-drug-information\" class=\"drug drug_general\">doxycycline</a>, <a href=\"topic.htm?path=imiquimod-drug-information\" class=\"drug drug_general\">imiquimod</a>, <a href=\"topic.htm?path=etanercept-including-biosimilars-of-etanercept-drug-information\" class=\"drug drug_general\">etanercept</a>, and oral <a href=\"topic.htm?path=tacrolimus-drug-information\" class=\"drug drug_general\">tacrolimus</a> [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/44,67-70\" class=\"abstract_t\">44,67-70</a>].</p><p class=\"headingAnchor\" id=\"H6313100\"><span class=\"h2\">Use</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Only pure, medical grade silicone should be used for soft tissue augmentation. In the United States, there are two commercially available products: Silikon 1000, and its more viscous counterpart, AdatoSil 5000. Due to its less viscous nature, Silikon 1000 is more suitable for cosmetic soft tissue injection [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/43\" class=\"abstract_t\">43</a>]. </p><p>The microdroplet serial puncture technique, defined as the injection of 0.01 mL or less at 2 to 10 mm intervals subdermally with a small diameter (eg, 27- to 30-gauge) needle, should be employed during treatment [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/44,71\" class=\"abstract_t\">44,71</a>]. In most cases, no more than 0.5 to 1 mL of silicone should be injected per treatment session, and additional treatments should be separated by no less than one month [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/44\" class=\"abstract_t\">44</a>]. Undercorrection is the goal of treatment, as further improvement occurs as new collagen forms around silicone microdroplets. Optimal collagen formation is attained by approximately 12 weeks [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/44\" class=\"abstract_t\">44</a>].</p><p class=\"headingAnchor\" id=\"H875327\"><span class=\"h1\">AUTOLOGOUS FAT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Autologous fat transfer has been used for the correction of a variety of contour defects involving the face or body [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/72-78\" class=\"abstract_t\">72-78</a>]. The main advantage of autologous fat in comparison to other soft tissue fillers is the lack of risk for hypersensitivity or foreign body reactions. </p><p>Objective data on the longevity of transplanted fat are limited, and the retention of fat has been estimated to range from 20 to 80 percent [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/79-82\" class=\"abstract_t\">79-82</a>]. A variety of factors, including the harvesting technique, type of fat implanted, treatment site, injection technique, and experience of the injector can influence the efficacy of treatment [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/83-88\" class=\"abstract_t\">83-88</a>]. The advent of new harvesting and processing techniques, such as the addition of platelet-rich plasma or adipose-derived stem cells to transplanted fat, may lead to improved viability [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/83-87,89\" class=\"abstract_t\">83-87,89</a>]. Additional studies are necessary to explore the in vivo efficacy of these interventions.</p><p>Although the risk for hypersensitivity reactions is negligible, fat transfer procedures can be complicated by morbidity in the donor site, prolonged edema, infections, contour irregularities, and necrosis or calcification of the injected fat [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/90\" class=\"abstract_t\">90</a>]. Fat emboli leading to stroke and vision loss have also been reported in association with this autologous fat transfer [<a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/1,2,91-101\" class=\"abstract_t\">1,2,91-101</a>].</p><p class=\"headingAnchor\" id=\"H881865\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Injectable filling agents are useful for the replacement volume lost from soft tissue due to a variety of factors. Permanent soft tissue fillers persist indefinitely in tissues. The potential adverse effects of permanent filling agents must be considered carefully prior to use. (See <a href=\"#H879724\" class=\"local\">'Introduction'</a> above and <a href=\"#H3502728\" class=\"local\">'Precautions'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Bellafill, a product that contains polymethylmethacrylate microspheres and bovine collagen, is injected into the deep reticular dermis and fills soft tissue through the stimulation of new collagen formation. Due to the bovine collagen component, patients must be skin-tested prior to use. Treatment of the lips and areas of thin skin should be avoided. (See <a href=\"#H15763905\" class=\"local\">'Polymethylmethacrylate microspheres'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hydrogel polymers, including polyacrylamide and polyalkylimide hydrogels, augment soft tissue through a direct volume filling effect. Injections are placed into the subcutaneous fat. (See <a href=\"#H15763919\" class=\"local\">'Hydrogel polymers'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Liquid injectable silicone exerts its effects through acting as a direct volume filler and a stimulant for new collagen formation. Only pure, medical grade silicone should be used for injection, and a microdroplet serial puncture technique should be used. When improper formulations or injection techniques are utilized, silicone can induce severe adverse effects. Liquid injectable silicone should be used only by expert and experienced injectors. (See <a href=\"#H6313044\" class=\"local\">'Liquid injectable silicone'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Autologous fat transfer provides soft tissue augmentation without the risk for allergic reactions. The degree persistence of fat in the treated site is variable and is dependent on multiple factors, such as clinician technique and treatment location. Fat embolus is a potential serious complication of this procedure. (See <a href=\"#H875327\" class=\"local\">'Autologous fat'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/1\" class=\"nounderline abstract_t\">Park SW, Woo SJ, Park KH, et al. Iatrogenic retinal artery occlusion caused by cosmetic facial filler injections. Am J Ophthalmol 2012; 154:653.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/2\" class=\"nounderline abstract_t\">Lazzeri D, Agostini T, Figus M, et al. Blindness following cosmetic injections of the face. Plast Reconstr Surg 2012; 129:995.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/3\" class=\"nounderline abstract_t\">Lemperle G, Knapp TR, Sadick NS, Lemperle SM. ArteFill permanent injectable for soft tissue augmentation: I. Mechanism of action and injection techniques. Aesthetic Plast Surg 2010; 34:264.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/4\" class=\"nounderline abstract_t\">Lemperle G, Romano JJ, Busso M. Soft tissue augmentation with artecoll: 10-year history, indications, techniques, and complications. Dermatol Surg 2003; 29:573.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/5\" class=\"nounderline abstract_t\">Lemperle G, Sadick NS, Knapp TR, Lemperle SM. ArteFill permanent injectable for soft tissue augmentation: II. Indications and applications. Aesthetic Plast Surg 2010; 34:273.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/6\" class=\"nounderline abstract_t\">Cohen SR, Holmes RE. Artecoll: a long-lasting injectable wrinkle filler material: Report of a controlled, randomized, multicenter clinical trial of 251 subjects. Plast Reconstr Surg 2004; 114:964.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/7\" class=\"nounderline abstract_t\">Cohen SR, Berner CF, Busso M, et al. ArteFill: a long-lasting injectable wrinkle filler material--summary of the U.S. Food and Drug Administration trials and a progress report on 4- to 5-year outcomes. Plast Reconstr Surg 2006; 118:64S.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/8\" class=\"nounderline abstract_t\">Cohen SR, Berner CF, Busso M, et al. Five-year safety and efficacy of a novel polymethylmethacrylate aesthetic soft tissue filler for the correction of nasolabial folds. Dermatol Surg 2007; 33 Suppl 2:S222.</a></li><li class=\"breakAll\">Artefill Instructions for Use. San Diego, CA: Suneva Medical, Inc; 2009.</li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/10\" class=\"nounderline abstract_t\">Bagal A, Dahiya R, Tsai V, Adamson PA. Clinical experience with polymethylmethacrylate microspheres (Artecoll) for soft-tissue augmentation: a retrospective review. Arch Facial Plast Surg 2007; 9:275.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/11\" class=\"nounderline abstract_t\">Lemperle G, de Fazio S, Nicolau P. ArteFill: a third-generation permanent dermal filler and tissue stimulator. Clin Plast Surg 2006; 33:551.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/12\" class=\"nounderline abstract_t\">Chrastil-LaTowsky B, Wesley NO, MacGregor JL, et al. Delayed inflammatory reaction to bio-alcamid polyacrylamide gel used for soft-tissue augmentation. Arch Dermatol 2009; 145:1309.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/13\" class=\"nounderline abstract_t\">Breiting V, Aasted A, J&oslash;rgensen A, et al. A study on patients treated with polyacrylamide hydrogel injection for facial corrections. Aesthetic Plast Surg 2004; 28:45.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/14\" class=\"nounderline abstract_t\">von Buelow S, von Heimburg D, Pallua N. Efficacy and safety of polyacrylamide hydrogel for facial soft-tissue augmentation. Plast Reconstr Surg 2005; 116:1137.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/15\" class=\"nounderline abstract_t\">von Buelow S, Pallua N. Efficacy and safety of polyacrylamide hydrogel for facial soft-tissue augmentation in a 2-year follow-up: a prospective multicenter study for evaluation of safety and aesthetic results in 101 patients. Plast Reconstr Surg 2006; 118:85S.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/16\" class=\"nounderline abstract_t\">De Santis G, Jacob V, Baccarani A, et al. Polyacrylamide hydrogel injection in the management of human immunodeficiency virus-related facial lipoatrophy: a 2-year clinical experience. Plast Reconstr Surg 2008; 121:644.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/17\" class=\"nounderline abstract_t\">Wolters M, Lampe H. Prospective multicenter study for evaluation of safety, efficacy, and esthetic results of cross-linked polyacrylamide hydrogel in 81 patients. Dermatol Surg 2009; 35 Suppl 1:338.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/18\" class=\"nounderline abstract_t\">Narins RS, Coleman WP 3rd, Rohrich R, et al. 12-Month controlled study in the United States of the safety and efficacy of a permanent 2.5% polyacrylamide hydrogel soft-tissue filler. Dermatol Surg 2010; 36 Suppl 3:1819.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/19\" class=\"nounderline abstract_t\">Pallua N, Wolter TP. A 5-year assessment of safety and aesthetic results after facial soft-tissue augmentation with polyacrylamide hydrogel (Aquamid): a prospective multicenter study of 251 patients. Plast Reconstr Surg 2010; 125:1797.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/20\" class=\"nounderline abstract_t\">Negredo E, Puig J, Aldea D, et al. Four-year safety with polyacrylamide hydrogel to correct antiretroviral-related facial lipoatrophy. AIDS Res Hum Retroviruses 2009; 25:451.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/21\" class=\"nounderline abstract_t\">Kawamura JY, Domaneschi C, Migliari DA, Sousa SO. Foreign body reaction due to skin filler: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006; 101:469.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/22\" class=\"nounderline abstract_t\">Niedzielska I, Pajak J, Drugacz J. Late complications after polyacrylamide hydrogel injection into facial soft tissues. Aesthetic Plast Surg 2006; 30:377.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/23\" class=\"nounderline abstract_t\">Goldman MP. Pressure-induced migration of a permanent soft tissue filler. Dermatol Surg 2009; 35 Suppl 1:403.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/24\" class=\"nounderline abstract_t\">Alijotas-Reig J, Garcia-Gimenez V, Mir&oacute;-Mur F, Vilardell-Tarr&eacute;s M. Delayed immune-mediated adverse effects related to polyacrylamide dermal fillers: clinical findings, management, and follow-up. Dermatol Surg 2009; 35 Suppl 1:360.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/25\" class=\"nounderline abstract_t\">Liu HL, Cheung WY. Complications of polyacrylamide hydrogel (PAAG) injection in facial augmentation. J Plast Reconstr Aesthet Surg 2010; 63:e9.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/26\" class=\"nounderline abstract_t\">Protopapa C, Sito G, Caporale D, Cammarota N. Bio-Alcamid in drug-induced lipodystrophy. J Cosmet Laser Ther 2003; 5:226.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/27\" class=\"nounderline abstract_t\">Treacy PJ, Goldberg DJ. Use of a biopolymer polyalkylimide filler for facial lipodystrophy in HIV-positive patients undergoing treatment with antiretroviral drugs. Dermatol Surg 2006; 32:804.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/28\" class=\"nounderline abstract_t\">Lahiri A, Waters R. Experience with Bio-Alcamid, a new soft tissue endoprosthesis. J Plast Reconstr Aesthet Surg 2007; 60:663.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/29\" class=\"nounderline abstract_t\">Loutfy MR, Raboud JM, Antoniou T, et al. Immediate versus delayed polyalkylimide gel injections to correct facial lipoatrophy in HIV-positive patients. AIDS 2007; 21:1147.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/30\" class=\"nounderline abstract_t\">Ramon Y, Fodor L, Ullmann Y. Preliminary experiences with Bio-Alcamid in HIV facial lipoatrophy. Dermatology 2007; 214:151.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/31\" class=\"nounderline abstract_t\">H&ouml;nig J. Cheek augmentation with Bio-Alcamid in facial lipoatrophy in HIV seropositive patients. J Craniofac Surg 2008; 19:1085.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/32\" class=\"nounderline abstract_t\">Antoniou T, Raboud JM, Kovacs C, et al. Long-term efficacy and safety of polyalkylimide gel for the treatment of HIV-associated lipoatrophy. AIDS Care 2009; 21:1247.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/33\" class=\"nounderline abstract_t\">Pacini S, Ruggiero M, Morucci G, et al. Bio-alcamid: a novelty for reconstructive and cosmetic surgery. Ital J Anat Embryol 2002; 107:209.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/34\" class=\"nounderline abstract_t\">Claoue BL, Rabineau P. The polyalkylimide gel: experience with Bio-Alcamid. Semin Cutan Med Surg 2004; 23:236.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/35\" class=\"nounderline abstract_t\">Karim RB, Hage JJ, van Rozelaar L, et al. Complications of polyalkylimide 4% injections (Bio-Alcamid): a report of 18 cases. J Plast Reconstr Aesthet Surg 2006; 59:1409.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/36\" class=\"nounderline abstract_t\">Serrano C, Serrano S. [Delayed infection after Bio-alcamid implantation]. Actas Dermosifiliogr 2006; 97:460.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/37\" class=\"nounderline abstract_t\">Goldan O, Georgiou I, Farber N, et al. Late-onset facial abscess formation after cosmetic soft tissue augmentation with bio-alcamid. Aesthet Surg J 2007; 27:416.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/38\" class=\"nounderline abstract_t\">Goldan O, Georgiou I, Grabov-Nardini G, et al. Early and late complications after a nonabsorbable hydrogel polymer injection: a series of 14 patients and novel management. Dermatol Surg 2007; 33 Suppl 2:S199.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/39\" class=\"nounderline abstract_t\">G&oacute;mez-de la Fuente E, Alvarez-Fern&aacute;ndez JG, Pinedo F, et al. [Cutaneous adverse reaction to Bio-Alcamid implant]. Actas Dermosifiliogr 2007; 98:271.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/40\" class=\"nounderline abstract_t\">Jones DH, Carruthers A, Fitzgerald R, et al. Late-appearing abscesses after injections of nonabsorbable hydrogel polymer for HIV-associated facial lipoatrophy. Dermatol Surg 2007; 33 Suppl 2:S193.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/41\" class=\"nounderline abstract_t\">Akrish S, Dayan D, Taicher S, et al. Foreign body granulomas after injection of Bio-alcamid for lip augmentation. Am J Otolaryngol 2009; 30:356.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/42\" class=\"nounderline abstract_t\">Ross AH, Malhotra R. Long-term orbitofacial complications of polyalkylimide 4% (bio-alcamid). Ophthal Plast Reconstr Surg 2009; 25:394.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/43\" class=\"nounderline abstract_t\">Jones DH. Semipermanent and permanent injectable fillers. Dermatol Clin 2009; 27:433.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/44\" class=\"nounderline abstract_t\">Prather CL, Jones DH. Liquid injectable silicone for soft tissue augmentation. Dermatol Ther 2006; 19:159.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/45\" class=\"nounderline abstract_t\">Hevia O. Six-year experience using 1,000-centistoke silicone oil in 916 patients for soft-tissue augmentation in a private practice setting. Dermatol Surg 2009; 35 Suppl 2:1646.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/46\" class=\"nounderline abstract_t\">Jones DH, Carruthers A, Orentreich D, et al. Highly purified 1000-cSt silicone oil for treatment of human immunodeficiency virus-associated facial lipoatrophy: an open pilot trial. Dermatol Surg 2004; 30:1279.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/47\" class=\"nounderline abstract_t\">Chen F, Carruthers A, Humphrey S, Carruthers J. HIV-associated facial lipoatrophy treated with injectable silicone oil: a pilot study. J Am Acad Dermatol 2013; 69:431.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/48\" class=\"nounderline abstract_t\">Moscona RA, Fodor L. A retrospective study on liquid injectable silicone for lip augmentation: long-term results and patient satisfaction. J Plast Reconstr Aesthet Surg 2010; 63:1694.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/49\" class=\"nounderline abstract_t\">Orentreich D, Leone AS. A case of HIV-associated facial lipoatrophy treated with 1000-cs liquid injectable silicone. Dermatol Surg 2004; 30:548.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/50\" class=\"nounderline abstract_t\">Narins RS, Beer K. Liquid injectable silicone: a review of its history, immunology, technical considerations, complications, and potential. Plast Reconstr Surg 2006; 118:77S.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/51\" class=\"nounderline abstract_t\">Duffy DM. Liquid silicone for soft tissue augmentation. Dermatol Surg 2005; 31:1530.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/52\" class=\"nounderline abstract_t\">Balkin SW. Injectable silicone and the foot: a 41-year clinical and histologic history. Dermatol Surg 2005; 31:1555.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/53\" class=\"nounderline abstract_t\">Barnett JG, Barnett CR. Treatment of acne scars with liquid silicone injections: 30-year perspective. Dermatol Surg 2005; 31:1542.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/54\" class=\"nounderline abstract_t\">Zappi E, Barnett JG, Zappi M, Barnett CR. The long-term host response to liquid silicone injected during soft tissue augmentation procedures: a microscopic appraisal. Dermatol Surg 2007; 33 Suppl 2:S186.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/55\" class=\"nounderline abstract_t\">Wilkie TF. Late development of granuloma after liquid silicone injections. Plast Reconstr Surg 1977; 60:179.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/56\" class=\"nounderline abstract_t\">Milojevic B. Complications after silicone injection therapy in aesthetic plastic surgery. Aesthetic Plast Surg 1982; 6:203.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/57\" class=\"nounderline abstract_t\">Travis WD, Balogh K, Abraham JL. Silicone granulomas: report of three cases and review of the literature. Hum Pathol 1985; 16:19.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/58\" class=\"nounderline abstract_t\">Granick MS, Solomon MP, Mosely LH, McGrath MH. Devastating granulomata of the lower extremities resulting from cosmetic injection of adulturated liquid silicone. Plast Reconstr Surg 1994; 94:536.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/59\" class=\"nounderline abstract_t\">Rapaport MJ, Vinnik C, Zarem H. Injectable silicone: cause of facial nodules, cellulitis, ulceration, and migration. Aesthetic Plast Surg 1996; 20:267.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/60\" class=\"nounderline abstract_t\">Ficarra G, Mosqueda-Taylor A, Carlos R. Silicone granuloma of the facial tissues: a report of seven cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002; 94:65.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/61\" class=\"nounderline abstract_t\">Pimentel L, Barnadas M, Vidal D, et al. Simultaneous presentation of silicone and silica granuloma: a case report. Dermatology 2002; 205:162.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/62\" class=\"nounderline abstract_t\">Poveda R, Bag&aacute;n JV, Murillo J, Jim&eacute;nez Y. Granulomatous facial reaction to injected cosmetic fillers--a presentation of five cases. Med Oral Patol Oral Cir Bucal 2006; 11:E1.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/63\" class=\"nounderline abstract_t\">Schwartzfarb EM, Hametti JM, Romanelli P, Ricotti C. Foreign body granuloma formation secondary to silicone injection. Dermatol Online J 2008; 14:20.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/64\" class=\"nounderline abstract_t\">Altmeyer MD, Anderson LL, Wang AR. Silicone migration and granuloma formation. J Cosmet Dermatol 2009; 8:92.</a></li><li class=\"breakAll\">Orentreich DS, Orentreich N. Injectable fluid silicone. In: Dermatologic surgery: Principles and Practice, 1st ed, Roenigk R, Roenigk HH (Eds), Marcel Dekker, New York 1989. p.1349.</li><li class=\"breakAll\">Duffy DM. Injectable liquid silicone: New perspectives. In: Tissue Augmentation in Clinical Practice: Procedures and Techniques, 1st ed, Klein A (Ed), Marcel Dekker, New York 1998. p.237.</li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/67\" class=\"nounderline abstract_t\">Baumann LS, Halem ML. Lip silicone granulomatous foreign body reaction treated with aldara (imiquimod 5%). Dermatol Surg 2003; 29:429.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/68\" class=\"nounderline abstract_t\">Arin MJ, B&auml;te J, Krieg T, Hunzelmann N. Silicone granuloma of the face treated with minocycline. J Am Acad Dermatol 2005; 52:53.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/69\" class=\"nounderline abstract_t\">Pasternack FR, Fox LP, Engler DE. Silicone granulomas treated with etanercept. Arch Dermatol 2005; 141:13.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/70\" class=\"nounderline abstract_t\">Alijotas-Reig J, Garcia-Gimenez V, Vilardell-Tarr&eacute;s M. Tacrolimus in the treatment of chronic and refractory late-onset immune-mediated adverse effects related to silicone injections. Dermatol Surg 2012; 38:38.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/71\" class=\"nounderline abstract_t\">Orentreich DS. Liquid injectable silicone: techniques for soft tissue augmentation. Clin Plast Surg 2000; 27:595.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/72\" class=\"nounderline abstract_t\">Coleman SR. Facial recontouring with lipostructure. Clin Plast Surg 1997; 24:347.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/73\" class=\"nounderline abstract_t\">Butterwick KJ, Lack EA. Facial volume restoration with the fat autograft muscle injection technique. Dermatol Surg 2003; 29:1019.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/74\" class=\"nounderline abstract_t\">Donofrio LM. Structural autologous lipoaugmentation: a pan-facial technique. Dermatol Surg 2000; 26:1129.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/75\" class=\"nounderline abstract_t\">Donofrio LM. Techniques in facial fat grafting. Aesthet Surg J 2008; 28:681.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/76\" class=\"nounderline abstract_t\">Glasgold M, Lam SM, Glasgold R. Autologous fat grafting for cosmetic enhancement of the perioral region. Facial Plast Surg Clin North Am 2007; 15:461.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/77\" class=\"nounderline abstract_t\">Kanchwala SK, Glatt BS, Conant EF, Bucky LP. Autologous fat grafting to the reconstructed breast: the management of acquired contour deformities. Plast Reconstr Surg 2009; 124:409.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/78\" class=\"nounderline abstract_t\">Pereira LH, Nicaretta B, Sterodimas A. Correction of liposuction sequelae by autologous fat transplantation. Aesthetic Plast Surg 2011; 35:1000.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/79\" class=\"nounderline abstract_t\">Ersek RA. Transplantation of purified autologous fat: a 3-year follow-up is disappointing. Plast Reconstr Surg 1991; 87:219.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/80\" class=\"nounderline abstract_t\">Coleman SR. Long-term survival of fat transplants: controlled demonstrations. Aesthetic Plast Surg 1995; 19:421.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/81\" class=\"nounderline abstract_t\">Fulton JE, Suarez M, Silverton K, Barnes T. Small volume fat transfer. Dermatol Surg 1998; 24:857.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/82\" class=\"nounderline abstract_t\">Fournier PF. Fat grafting: my technique. Dermatol Surg 2000; 26:1117.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/83\" class=\"nounderline abstract_t\">Moscatello DK, Schiavi J, Marquart JD, Lawrence N. Collagenase-assisted fat dissociation for autologous fat transfer. Dermatol Surg 2008; 34:1314.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/84\" class=\"nounderline abstract_t\">Cervelli V, Palla L, Pascali M, et al. Autologous platelet-rich plasma mixed with purified fat graft in aesthetic plastic surgery. Aesthetic Plast Surg 2009; 33:716.</a></li><li class=\"breakAll\">Alexander RW. Use of platelet-rich plasma to enhance effectiveness of autologous fat grafting. In: Autologous Fat Transfer: Art, Science, and Clinical Practice, Shiffman MA (Ed), Springer, Heidelberg 2010. p.87.</li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/86\" class=\"nounderline abstract_t\">Yoshimura K, Sato K, Aoi N, et al. Cell-assisted lipotransfer for facial lipoatrophy: efficacy of clinical use of adipose-derived stem cells. Dermatol Surg 2008; 34:1178.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/87\" class=\"nounderline abstract_t\">Sterodimas A, de Faria J, Nicaretta B, et al. Cell-assisted lipotransfer. Aesthet Surg J 2010; 30:78.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/88\" class=\"nounderline abstract_t\">Eremia S, Newman N. Long-term follow-up after autologous fat grafting: analysis of results from 116 patients followed at least 12 months after receiving the last of a minimum of two treatments. Dermatol Surg 2000; 26:1150.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/89\" class=\"nounderline abstract_t\">Sterodimas A, de Faria J, Nicaretta B, Pitanguy I. Tissue engineering with adipose-derived stem cells (ADSCs): current and future applications. J Plast Reconstr Aesthet Surg 2010; 63:1886.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/90\" class=\"nounderline abstract_t\">Cheng JT, Perkins SW, Hamilton MM. Collagen and injectable fillers. Otolaryngol Clin North Am 2002; 35:73.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/91\" class=\"nounderline abstract_t\">Teimourian B. Blindness following fat injections. Plast Reconstr Surg 1988; 82:361.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/92\" class=\"nounderline abstract_t\">Dreizen NG, Framm L. Sudden unilateral visual loss after autologous fat injection into the glabellar area. Am J Ophthalmol 1989; 107:85.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/93\" class=\"nounderline abstract_t\">Egido JA, Arroyo R, Marcos A, Jim&eacute;nez-Alfaro I. Middle cerebral artery embolism and unilateral visual loss after autologous fat injection into the glabellar area. Stroke 1993; 24:615.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/94\" class=\"nounderline abstract_t\">Feinendegen DL, Baumgartner RW, Schroth G, et al. Middle cerebral artery occlusion AND ocular fat embolism after autologous fat injection in the face. J Neurol 1998; 245:53.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/95\" class=\"nounderline abstract_t\">Danesh-Meyer HV, Savino PJ, Sergott RC. Case reports and small case series: ocular and cerebral ischemia following facial injection of autologous fat. Arch Ophthalmol 2001; 119:777.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/96\" class=\"nounderline abstract_t\">Yoon SS, Chang DI, Chung KC. Acute fatal stroke immediately following autologous fat injection into the face. Neurology 2003; 61:1151.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/97\" class=\"nounderline abstract_t\">Thaunat O, Thaler F, Loirat P, et al. Cerebral fat embolism induced by facial fat injection. Plast Reconstr Surg 2004; 113:2235.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/98\" class=\"nounderline abstract_t\">Mori K, Ohta K, Nagano S, et al. [A case of ophthalmic artery obstruction following autologous fat injection in the glabellar area]. Nippon Ganka Gakkai Zasshi 2007; 111:22.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/99\" class=\"nounderline abstract_t\">Park SH, Sun HJ, Choi KS. Sudden unilateral visual loss after autologous fat injection into the nasolabial fold. Clin Ophthalmol 2008; 2:679.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/100\" class=\"nounderline abstract_t\">Gleeson CM, Lucas S, Langrish CJ, Barlow RJ. Acute fatal fat tissue embolism after autologous fat transfer in a patient with lupus profundus. Dermatol Surg 2011; 37:111.</a></li><li><a href=\"https://www.uptodate.com/contents/injectable-soft-tissue-fillers-permanent-agents/abstract/101\" class=\"nounderline abstract_t\">Park YH, Kim KS. Images in clinical medicine. Blindness after fat injections. N Engl J Med 2011; 365:2220.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 13652 Version 12.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H881865\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H879724\" id=\"outline-link-H879724\">INTRODUCTION</a></li><li><a href=\"#H3502728\" id=\"outline-link-H3502728\">PRECAUTIONS</a></li><li><a href=\"#H15763905\" id=\"outline-link-H15763905\">POLYMETHYLMETHACRYLATE MICROSPHERES</a><ul><li><a href=\"#H873135\" id=\"outline-link-H873135\">Mechanism of action</a></li><li><a href=\"#H873242\" id=\"outline-link-H873242\">Efficacy</a></li><li><a href=\"#H873142\" id=\"outline-link-H873142\">Use</a></li><li><a href=\"#H873149\" id=\"outline-link-H873149\">Adverse effects</a></li></ul></li><li><a href=\"#H15763919\" id=\"outline-link-H15763919\">HYDROGEL POLYMERS</a><ul><li><a href=\"#H873899\" id=\"outline-link-H873899\">Polyacrylamide hydrogel</a><ul><li><a href=\"#H874204\" id=\"outline-link-H874204\">- Mechanism of action</a></li><li><a href=\"#H874220\" id=\"outline-link-H874220\">- Efficacy</a></li><li><a href=\"#H874440\" id=\"outline-link-H874440\">- Use</a></li><li><a href=\"#H874302\" id=\"outline-link-H874302\">- Adverse effects</a></li></ul></li><li><a href=\"#H8872500\" id=\"outline-link-H8872500\">Polyalkylimide hydrogel</a><ul><li><a href=\"#H882078\" id=\"outline-link-H882078\">- Mechanism of action</a></li><li><a href=\"#H882085\" id=\"outline-link-H882085\">- Efficacy and use</a></li><li><a href=\"#H882092\" id=\"outline-link-H882092\">- Adverse effects</a></li></ul></li></ul></li><li><a href=\"#H6313044\" id=\"outline-link-H6313044\">LIQUID INJECTABLE SILICONE</a><ul><li><a href=\"#H6313086\" id=\"outline-link-H6313086\">Mechanism of action</a></li><li><a href=\"#H6313093\" id=\"outline-link-H6313093\">Efficacy and safety</a></li><li><a href=\"#H6313100\" id=\"outline-link-H6313100\">Use</a></li></ul></li><li><a href=\"#H875327\" id=\"outline-link-H875327\">AUTOLOGOUS FAT</a></li><li><a href=\"#H881865\" id=\"outline-link-H881865\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DERM/13652|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=DERM/54021\" class=\"graphic graphic_figure\">- Placement of injectable soft tissue fillers</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=central-and-branch-retinal-artery-occlusion\" class=\"medical medical_review\">Central and branch retinal artery occlusion</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=injectable-soft-tissue-fillers-overview-of-clinical-use\" class=\"medical medical_review\">Injectable soft tissue fillers: Overview of clinical use</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=injectable-soft-tissue-fillers-temporary-agents\" class=\"medical medical_review\">Injectable soft tissue fillers: Temporary agents</a></li></ul></div></div>","javascript":null}